344 related articles for article (PubMed ID: 36132858)
1.
Singh N; Marets C; Boudon J; Millot N; Saviot L; Maurizi L
Nanoscale Adv; 2021 Mar; 3(5):1209-1229. PubMed ID: 36132858
[TBL] [Abstract][Full Text] [Related]
2. In-vitro in-vivo correlation (IVIVC) in nanomedicine: Is protein corona the missing link?
Jain P; Pawar RS; Pandey RS; Madan J; Pawar S; Lakshmi PK; Sudheesh MS
Biotechnol Adv; 2017 Nov; 35(7):889-904. PubMed ID: 28844973
[TBL] [Abstract][Full Text] [Related]
3. Nano-Bio Interactions in Cancer: From Therapeutics Delivery to Early Detection.
Liu Y; Wang J; Xiong Q; Hornburg D; Tao W; Farokhzad OC
Acc Chem Res; 2021 Jan; 54(2):291-301. PubMed ID: 33180454
[TBL] [Abstract][Full Text] [Related]
4. The impact of protein corona on the biological behavior of targeting nanomedicines.
Farshbaf M; Valizadeh H; Panahi Y; Fatahi Y; Chen M; Zarebkohan A; Gao H
Int J Pharm; 2022 Feb; 614():121458. PubMed ID: 35017025
[TBL] [Abstract][Full Text] [Related]
5. Recent Advances in Understanding the Protein Corona of Nanoparticles and in the Formulation of "Stealthy" Nanomaterials.
Rampado R; Crotti S; Caliceti P; Pucciarelli S; Agostini M
Front Bioeng Biotechnol; 2020; 8():166. PubMed ID: 32309278
[TBL] [Abstract][Full Text] [Related]
6. Research progress and application opportunities of nanoparticle-protein corona complexes.
Huang W; Xiao G; Zhang Y; Min W
Biomed Pharmacother; 2021 Jul; 139():111541. PubMed ID: 33848776
[TBL] [Abstract][Full Text] [Related]
7. Artificial engineering of the protein corona at bio-nano interfaces for improved cancer-targeted nanotherapy.
Khan S; Sharifi M; Gleghorn JP; Babadaei MMN; Bloukh SH; Edis Z; Amin M; Bai Q; Ten Hagen TLM; Falahati M; Cho WC
J Control Release; 2022 Aug; 348():127-147. PubMed ID: 35660636
[TBL] [Abstract][Full Text] [Related]
8. The Crown and the Scepter: Roles of the Protein Corona in Nanomedicine.
Cai R; Chen C
Adv Mater; 2019 Nov; 31(45):e1805740. PubMed ID: 30589115
[TBL] [Abstract][Full Text] [Related]
9. Insights into colloidal nanoparticle-protein corona interactions for nanomedicine applications.
Martínez-Negro M; González-Rubio G; Aicart E; Landfester K; Guerrero-Martínez A; Junquera E
Adv Colloid Interface Sci; 2021 Mar; 289():102366. PubMed ID: 33540289
[TBL] [Abstract][Full Text] [Related]
10. Biological Identity of Nanoparticles In Vivo: Clinical Implications of the Protein Corona.
Caracciolo G; Farokhzad OC; Mahmoudi M
Trends Biotechnol; 2017 Mar; 35(3):257-264. PubMed ID: 27663778
[TBL] [Abstract][Full Text] [Related]
11. Enhanced Competition at the Nano-Bio Interface Enables Comprehensive Characterization of Protein Corona Dynamics and Deep Coverage of Proteomes.
Ferdosi S; Stukalov A; Hasan M; Tangeysh B; Brown TR; Wang T; Elgierari EM; Zhao X; Huang Y; Alavi A; Lee-McMullen B; Chu J; Figa M; Tao W; Wang J; Goldberg M; O'Brien ES; Xia H; Stolarczyk C; Weissleder R; Farias V; Batzoglou S; Siddiqui A; Farokhzad OC; Hornburg D
Adv Mater; 2022 Nov; 34(44):e2206008. PubMed ID: 35986672
[TBL] [Abstract][Full Text] [Related]
12. How protein coronas determine the fate of engineered nanoparticles in biological environment.
Capjak I; Goreta SŠ; Jurašin DD; Vrček IV
Arh Hig Rada Toksikol; 2017 Dec; 68(4):245-253. PubMed ID: 29337683
[TBL] [Abstract][Full Text] [Related]
13.
Bai X; Wang J; Mu Q; Su G
Front Bioeng Biotechnol; 2021; 9():646708. PubMed ID: 33869157
[TBL] [Abstract][Full Text] [Related]
14. Distinct Proteins in Protein Corona of Nanoparticles Represent a Promising Venue for Endogenous Targeting - Part II: In vitro and in vivo Kinetics Study.
Sebak AA; Gomaa IEO; ElMeshad AN; Farag MH; Breitinger U; Breitinger HG; AbdelKader MH
Int J Nanomedicine; 2020; 15():9539-9556. PubMed ID: 33299308
[TBL] [Abstract][Full Text] [Related]
15. Nanotoxicology: advances and pitfalls in research methodology.
Azhdarzadeh M; Saei AA; Sharifi S; Hajipour MJ; Alkilany AM; Sharifzadeh M; Ramazani F; Laurent S; Mashaghi A; Mahmoudi M
Nanomedicine (Lond); 2015; 10(18):2931-52. PubMed ID: 26370561
[TBL] [Abstract][Full Text] [Related]
16. The Yin and Yang of the protein corona on the delivery journey of nanoparticles.
Wang YF; Zhou Y; Sun J; Wang X; Jia Y; Ge K; Yan Y; Dawson KA; Guo S; Zhang J; Liang XJ
Nano Res; 2023; 16(1):715-734. PubMed ID: 36156906
[TBL] [Abstract][Full Text] [Related]
17. The protein corona and its effects on nanoparticle-based drug delivery systems.
Li H; Wang Y; Tang Q; Yin D; Tang C; He E; Zou L; Peng Q
Acta Biomater; 2021 Jul; 129():57-72. PubMed ID: 34048973
[TBL] [Abstract][Full Text] [Related]
18. The interaction between nanoparticles-protein corona complex and cells and its toxic effect on cells.
Liu N; Tang M; Ding J
Chemosphere; 2020 Apr; 245():125624. PubMed ID: 31864050
[TBL] [Abstract][Full Text] [Related]
19. A Review for Uncovering the "Protein-Nanoparticle Alliance": Implications of the Protein Corona for Biomedical Applications.
Önal Acet B; Gül D; Stauber RH; Odabaşı M; Acet Ö
Nanomaterials (Basel); 2024 May; 14(10):. PubMed ID: 38786780
[TBL] [Abstract][Full Text] [Related]
20. The effects of protein corona on in vivo fate of nanocarriers.
Xiao Q; Zoulikha M; Qiu M; Teng C; Lin C; Li X; Sallam MA; Xu Q; He W
Adv Drug Deliv Rev; 2022 Jul; 186():114356. PubMed ID: 35595022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
